Author, as appears in the article.: Quindós G; Miranda-Cadena K; San-Millán R; Borroto-Esoda K; Cantón E; Linares-Sicilia MJ; Hamprecht A; Montesinos I; Tortorano AM; Prigitano A; Vidal-García M; Marcos-Arias C; Guridi A; Sanchez-Reus F; Machuca-Bárcena J; Rodríguez-Iglesias MA; Martín-Mazuelos E; Castro-Méndez C; López-Soria L; Ruiz-Gaitán A; Fernandez-Rivero M; Lorenzo D; Capilla J; Rezusta A; Pemán J; Guarro J; Pereira J; Pais C; Romeo O; Ezpeleta G; Jauregizar N; Angulo D; Eraso E
Department: Ciències Mèdiques Bàsiques
URV's Author/s: Capilla Luque, Javier / Guarro Artigas, Josep / LORENZO GUTIÉRREZ, DÀMARIS
Keywords: Scy-078 Micafungin Ibrexafungerp Eucast Caspofungin Candida Antifungal testing Antifungal resistance
Abstract: Background: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. Objective: The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. Methods: Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. Results: Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016–0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06–≥8 mg/L). Modal MICs/MIC50s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. Conclusion: Ibrexafungerp showed a potent in vitro activity against Candida.
Thematic Areas: Saúde coletiva Química Odontología Microbiology (medical) Microbiology Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Infectious diseases Immunology Geociências Farmacia Ensino Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Biotecnología Biodiversidade
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: josep.guarro@urv.cat javier.capilla@urv.cat
Author identifier: 0000-0002-7839-7568 0000-0002-0765-6403
Record's date: 2024-08-24
Papper version: info:eu-repo/semantics/publishedVersion
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Frontiers In Cellular And Infection Microbiology. 12
APA: Quindós G; Miranda-Cadena K; San-Millán R; Borroto-Esoda K; Cantón E; Linares-Sicilia MJ; Hamprecht A; Montesinos I; Tortorano AM; Prigitano A; Vidal- (2022). In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study. Frontiers In Cellular And Infection Microbiology, 12(), -. DOI: 10.3389/fcimb.2022.906563
Entity: Universitat Rovira i Virgili
Journal publication year: 2022
Publication Type: Journal Publications
Repositori URV